Buy 3 and get the 4th FREE!* | Learn More >>
PACT Antibody
Primary Antibodies

PACT Antibody #12277

Reviews ()
Citations (0)

We recommend the following alternatives

# Product Name Application Reactivity
  • WB
  • IP
H Mk

Supporting Data

MW (kDa) 30

Application Key:

  • W-Western
  • IP-Immunoprecipitation
  • IHC-Immunohistochemistry
  • ChIP-Chromatin Immunoprecipitation
  • IF-Immunofluorescence
  • F-Flow Cytometry
  • E-P-ELISA-Peptide

Species Cross-Reactivity Key:

  • H-Human
  • M-Mouse
  • R-Rat
  • Hm-Hamster
  • Mk-Monkey
  • Mi-Mink
  • C-Chicken
  • Dm-D. melanogaster
  • X-Xenopus
  • Z-Zebrafish
  • B-Bovine
  • Dg-Dog
  • Pg-Pig
  • Sc-S. cerevisiae
  • Ce-C. elegans
  • Hr-Horse
  • All-All Species Expected


Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

PACT Antibody recognizes endogenous levels of total PACT protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human PACT protein. Antibodies are purified by protein A and peptide affinity chromatography.


PACT (protein activator of protein kinase R) is a double stranded RNA binding protein and a cellular activator of PKR (protein kinase R), a kinase that mediates the antiviral and antiproliferative actions of interferon (1). Stress signals such as serum starvation and arsenite treatment induces PACT to heterodimerize with PKR, resulting in the phosphorylation of eIF-2α and inhibition of protein synthesis (1,2). PACT has also been shown to play a role in RNA-mediated gene silencing by stimulating the activity of Dicer, thereby affecting the efficiency of miRNA accumulation and siRNA gene silencing (3,4). More recently, PACT has been shown to interact with RIG-I, a sensor of viral nucleic acids, and stimulates RIG-I-induced type I interferon production (5). Researchers have found that mutations in PACT are associated with dystonia, a movement disorder where patients develop involuntary muscle contractions and postures (6-8).

  1. Patel, R.C. and Sen, G.C. (1998) EMBO J 17, 4379-90.
  2. Patel, C.V. et al. (2000) J Biol Chem 275, 37993-8.
  3. Lee, Y. et al. (2006) EMBO J 25, 522-32.
  4. Koscianska, E. et al. (2011) PLoS One 6, e28548.
  5. Kok, K.H. et al. (2011) Cell Host Microbe 9, 299-309.
  6. Bragg, D.C. et al. (2011) Neurobiol Dis 42, 136-47.
  7. Camargos, S. et al. (2008) Lancet Neurol 7, 207-15.
  8. Seibler, P. et al. (2008) Lancet Neurol 7, 380-1.

Pathways & Proteins

Explore pathways + proteins related to this product.

For Research Use Only. Not For Use In Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

To Purchase # 12277